These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36368161)

  • 1. Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.
    Mahtani R; Niyazov A; Arondekar B; Lewis K; Rider A; Massey L; Lux MP
    Breast; 2022 Dec; 66():236-244. PubMed ID: 36368161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
    Mahtani R; Niyazov A; Arondekar B; Lewis K; Rider A; Massey L; Lux MP
    BMC Cancer; 2022 Dec; 22(1):1343. PubMed ID: 36550413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.
    Mahtani R; Niyazov A; Lewis K; Rider A; Massey L; Arondekar B; Lux MP
    Adv Ther; 2023 Jan; 40(1):331-348. PubMed ID: 36333567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics, treatment patterns, and outcomes in adult patients with germline
    Obeid E; Parikh RC; Esterberg E; Arondekar B; Hitchens A; Arruda LS; Niyazov A; Whitaker K
    Front Oncol; 2024; 14():1341665. PubMed ID: 38817906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
    Wood R; Mitra D; de Courcy J; Iyer S
    Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
    O'Shaughnessy J; Brezden-Masley C; Cazzaniga M; Dalvi T; Walker G; Bennett J; Ohsumi S
    Breast Cancer Res; 2020 Oct; 22(1):114. PubMed ID: 33109210
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Mahtani R; Niyazov A; Arondekar B; Lewis K; Rider A; Massey L; Lux MP
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA.
    Ndirangu K; Chabot I; Lewis K; Lambert A; Zhao Q; Lucero M; Meier G
    Future Oncol; 2024; 20(25):1807-1824. PubMed ID: 38861292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
    Litton JK; Hurvitz SA; Mina LA; Rugo HS; Lee KH; Gonçalves A; Diab S; Woodward N; Goodwin A; Yerushalmi R; Roché H; Im YH; Eiermann W; Quek RGW; Usari T; Lanzalone S; Czibere A; Blum JL; Martin M; Ettl J
    Ann Oncol; 2020 Nov; 31(11):1526-1535. PubMed ID: 32828825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world multi-country study of
    Lux MP; Lewis K; Rider A; Niyazov A
    Future Oncol; 2022 Mar; 18(9):1089-1101. PubMed ID: 35098723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of male patients with HR+/HER2- advanced breast cancer receiving palbociclib in the real-world POLARIS study.
    Blum JL; DiCristo C; Gordon D; Karuturi MS; Oubre D; Jepsen E; Cuevas J; Lakhanpal S; Montelongo MZ; Zhang Z; Cappelleri JC; Wang Y; Tripathy D
    Breast Cancer Res Treat; 2024 Feb; 203(3):463-475. PubMed ID: 37903899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown,
    Lux MP; Lewis K; Rider A; Niyazov A
    Breast Care (Basel); 2022 Oct; 17(5):460-469. PubMed ID: 36684399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What Proportion of BRCA-Associated Breast Cancer Is Human Epidermal Growth Factor 2-Low and Eligible for Additional Targeted Therapy?
    Forester E; Belsare A; Kim DW; Whitaker K; Obeid E; Goldstein LJ; Bleicher RJ; Daly MB; Williams AD
    J Surg Res; 2024 Jul; 299():217-223. PubMed ID: 38776577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
    Chen Z; Wang X; Li X; Zhou Y; Chen K
    J Int Med Res; 2021 Feb; 49(2):300060521991019. PubMed ID: 33541181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Awareness and Availability of Routine Germline
    Lux MP; Decker T; Runkel ED; Niyazov A; Quek RGW; Marschner N; Harbeck N
    Breast Care (Basel); 2022 Feb; 17(1):40-46. PubMed ID: 35350106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
    Xu B; Sun T; Shi Y; Cui J; Yin Y; Ouyang Q; Liu Q; Zhang Q; Chen Y; Wang S; Wang X; Tong Z; Zhong Y; Wang J; Yan M; Yan X; Wang C; Feng J; Wang X; Hu G; Cheng Y; Ge R; Zhu Z; Zhang W; Shao Z
    Breast Cancer Res Treat; 2023 Feb; 197(3):489-501. PubMed ID: 36459284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer.
    Savill KMZ; Ivanova J; Asgarisabet P; Falkenstein A; Balanean A; Niyazov A; Ryan JC; Kish J; Gajra A; Mahtani RL
    Oncologist; 2023 May; 28(5):414-424. PubMed ID: 36952230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
    Zhang M; Yu X; Wang J; Li Y; Cao L
    J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Petracci FE; Villarreal-Garza C; Argañaraz F; Abuin GG; Peñaloza J; Flores MA; Piazzoni L; Riggi C; Fabiano L; González L; Cieplinski B; Rivero S; Korbenfeld E; Mandó P
    Ecancermedicalscience; 2023; 17():1634. PubMed ID: 38414929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
    Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
    J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.